NewEdge Advisors’s Arcutis Biotherapeutics ARQT Stock Holding History

NewEdge Advisors’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-500	Closed	-$11.8K	–	4189
2026 Q1	$11.8K	Sell	500 -1,045	-68%	-$26.7K	﹤0.01%	3360
2025 Q4	$44.9K	Buy	1,545 +1,045	+209%	+$26.8K	﹤0.01%	2988
2025 Q3	$9.43K	Sell	500 -300	-38%	-$4.73K	﹤0.01%	3342
2025 Q2	$11.2K	Buy	800 +100	+14%	+$1.4K	﹤0.01%	3177
2025 Q1	$10.9K	Buy	+700	New	+$9.86K	﹤0.01%	3066
2023 Q3	–	Sell	-100	Closed	-$953	–	3472
2023 Q2	$953	Hold	100	–	–	﹤0.01%	3250
2023 Q1	$1.1K	Hold	100	–	–	﹤0.01%	3144
2022 Q4	$1	Buy	+100	New	+$1.75K	﹤0.01%	3979

Other funds holding ARQT

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

NewEdge Advisors's ARQT Position: Q2 2026 in Review

NewEdge Advisors sold out of Arcutis Biotherapeutics (ARQT) in Q2 2026, closing a stake of 500 shares — an estimated $11.8K sold.

NewEdge Advisors first reported a position in ARQT in Q4 2022 and held it in 8 quarters. The position peaked at $44.9K in Q4 2025. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

NewEdge Advisors reported no remaining Arcutis Biotherapeutics position as of Q2 2026 after selling out during the quarter.
NewEdge Advisors sold 500 Arcutis Biotherapeutics shares in Q2 2026, an estimated $11.8K.
NewEdge Advisors first reported a position in Arcutis Biotherapeutics in Q4 2022 and held it in 8 quarters.
NewEdge Advisors's Arcutis Biotherapeutics position peaked at $44.9K in Q4 2025.
272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.